Arvinas, Inc. (ARVN)
NASDAQ
Market Cap
$1.77B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
496 of 809
Rank in Industry
271 of 445
Largest Insider Buys in Sector
ARVN Stock Price History Chart
ARVN Stock Performance
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Insider Activity of Arvinas, Inc.
Over the last 12 months, insiders at Arvinas, Inc. have bought $0 and sold $516,809 worth of Arvinas, Inc. stock.
On average, over the past 5 years, insiders at Arvinas, Inc. have bought $25.51M and sold $37.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 285,714 shares for transaction amount of $20M was made by Ratcliffe Liam (director) on 2020‑12‑18.
List of Insider Buy and Sell Transactions, Arvinas, Inc.
| 2024-02-23 | Sale | Houston John G | President and CEO | 5,196 0.0095% | $47.05 | $244,472 | -26.62% | |
| 2024-02-23 | Sale | Cassidy Sean A | Chief Financial Officer | 1,702 0.0031% | $47.05 | $80,079 | -26.62% | |
| 2024-02-23 | Sale | Taylor Ian | Chief Scientific Officer | 1,701 0.0031% | $47.05 | $80,032 | -26.62% | |
| 2024-02-23 | Sale | Peck Ronald | Chief Medical Officer | 1,699 0.0031% | $47.05 | $79,938 | -26.62% | |
| 2023-08-11 | Sale | Peck Ronald | Chief Medical Officer | 1,324 0.0024% | $24.39 | $32,289 | +29.90% | |
| 2023-03-01 | Sale | Houston John G | President and CEO | 5,878 0.0107% | $29.53 | $173,577 | -14.21% | |
| 2023-03-01 | Sale | Cassidy Sean A | Chief Financial Officer | 1,745 0.0032% | $29.53 | $51,530 | -14.21% | |
| 2023-03-01 | Sale | Taylor Ian | Chief Scientific Officer | 1,051 0.0019% | $29.53 | $31,036 | -14.21% | |
| 2022-08-12 | Sale | Peck Ronald | Chief Medical Officer | 1,258 0.0024% | $54.84 | $68,994 | -40.58% | |
| 2022-04-14 | Sale | Morrison Briggs | 10,754 0.0202% | $67.03 | $720,888 | -36.79% | ||
| 2022-03-11 | Sale | Cassidy Sean A | Chief Financial Officer | 15,000 0.029% | $70.00 | $1.05M | -36.08% | |
| 2022-03-04 | Sale | Houston John G | President and CEO | 6,024 0.0113% | $63.94 | $385,175 | -31.76% | |
| 2022-03-04 | Sale | Cassidy Sean A | Chief Financial Officer | 1,593 0.003% | $63.94 | $101,856 | -31.76% | |
| 2022-03-04 | Sale | Taylor Ian | Chief Scientific Officer | 869 0.0016% | $63.94 | $55,564 | -31.76% | |
| 2022-02-15 | Sale | Taylor Ian | Chief Scientific Officer | 20,000 0.0378% | $73.02 | $1.46M | -38.58% | |
| 2022-01-14 | Sale | Morrison Briggs | director | 20,960 0.0385% | $65.55 | $1.37M | -29.61% | |
| 2021-12-30 | Sale | Peck Ronald | Chief Medical Officer | 20,000 0.0382% | $80.61 | $1.61M | -38.61% | |
| 2021-12-17 | Sale | Cassidy Sean A | Chief Financial Officer | 15,000 0.0271% | $70.00 | $1.05M | -32.08% | |
| 2021-12-16 | Sale | Ratcliffe Liam | director | 85,705 0.1636% | $69.36 | $5.94M | -27.43% | |
| 2021-12-15 | Sale | Ratcliffe Liam | director | 113,536 0.2076% | $66.81 | $7.58M | -27.70% |
Insider Historical Profitability
40%
| Houston John G | President and CEO | 1036681 1.6673% | $25.87 | 1 | 10 | +24.92% |
| Cassidy Sean A | Chief Financial Officer | 181916 0.3337% | $25.87 | 1 | 13 | +24.92% |
| Taylor Ian | Chief Scientific Officer | 147522 0.1849% | $25.87 | 1 | 12 | +66.46% |
| Peck Ronald | Chief Medical Officer | 67516 0.0545% | $25.87 | 0 | 8 | |
| RA CAPITAL MANAGEMENT, LLC | 3138412 5.7036% | $25.87 | 1 | 0 | +24.92% | |
| SHANNON TIMOTHY M | director | 1653128 3.0043% | $25.87 | 5 | 11 | +35.38% |
| Flynn James E | 10 percent owner | 411245 0.7474% | $25.87 | 1 | 0 | +24.92% |
| Loven Jakob | director | 312500 0.5679% | $25.87 | 1 | 0 | +24.92% |
| Ratcliffe Liam | director | 185686 0.3375% | $25.87 | 3 | 10 | +24.96% |
| 5AM VENTURES III, L.P. | 10 percent owner | 91162 0.1657% | $25.87 | 0 | 4 | |
| Kennedy Edward Moore Jr. | director | 42718 0.0776% | $25.87 | 2 | 0 | +130.98% |
| Morrison Briggs | 19976 0.0363% | $25.87 | 1 | 2 | <0.0001% | |
| Margus Bradley Albert | director | 2000 0.0036% | $25.87 | 1 | 5 | +24.92% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Ecor1 Capital Llc | $277.67M | 9.83 | 6.73M | 0% | +$0 | 7.06 | |
| The Vanguard Group | $260.05M | 9.21 | 6.3M | +29.85% | +$59.78M | 0.01 | |
| BlackRock | $226.8M | 8.03 | 5.49M | +2.6% | +$5.75M | 0.01 | |
| T. Rowe Price | $180.33M | 6.38 | 4.37M | +13.99% | +$22.14M | 0.02 | |
| RTW Investments, LP | $136.14M | 4.82 | 3.3M | -21.73% | -$37.8M | 2.01 | |
| Avidity Partners Management Lp | $123.23M | 4.36 | 2.99M | +<0.01% | +$3,013.44 | 4.47 | |
| Paradigm BioCapital Advisors LP | $107.94M | 3.82 | 2.61M | +180.78% | +$69.5M | 3.92 | |
| Bellevue Group | $98.69M | 3.49 | 2.39M | -4.66% | -$4.83M | 1.51 | |
| Fidelity Investments | $98.62M | 3.49 | 2.39M | +6.46% | +$5.98M | 0.01 | |
| Citadel Advisors LLC | $94.14M | 3.33 | 2.28M | -6.53% | -$6.58M | 0.06 | |
| JPMorgan Chase | $70.17M | 2.48 | 1.7M | -21.77% | -$19.52M | 0.01 | |
| Nextech Invest | $58.14M | 2.06 | 1.41M | -16.94% | -$11.86M | 9.48 | |
| State Street | $57.06M | 2.02 | 1.38M | +16.49% | +$8.08M | <0.01 | |
| Geode Capital Management | $54.22M | 1.92 | 1.31M | +16.99% | +$7.87M | 0.01 | |
| New Leaf Venture Partners | $53.23M | 1.88 | 1.29M | 0% | +$0 | 46.65 | |
| Commodore Capital, LP | $52.63M | 1.86 | 1.27M | +27.5% | +$11.35M | 3.71 | |
| Perceptive Advisors | $51.05M | 1.81 | 1.24M | +249.24% | +$36.43M | 0.03 | |
| Arrowmark Colorado Holdings Llc | $49.77M | 1.76 | 1.21M | -23.21% | -$15.04M | 0.12 | |
| Morgan Stanley | $27.89M | 0.99 | 675,509 | -2.59% | -$741,801.59 | <0.01 | |
| Adage Capital Partners Gp L L C | $26.01M | 0.92 | 630,000 | -20.2% | -$6.58M | 0.05 | |
| Vr Adviser Llc | $25.92M | 0.92 | 627,788 | 0% | +$0 | 1.26 | |
| Boxer Capital, LLC | $25.12M | 0.89 | 608,614 | 0% | +$0 | 1.26 | |
| Goldman Sachs | $24.54M | 0.87 | 594,403 | +80.42% | +$10.94M | 0.01 | |
| FINEPOINT CAPITAL LP | $22.25M | 0.79 | 539,100 | +6.82% | +$1.42M | 4.04 | |
| Charles Schwab | $21.8M | 0.77 | 528,055 | +12.48% | +$2.42M | 0.01 | |
| Northern Trust | $21.02M | 0.74 | 509,127 | +3.64% | +$738,581.74 | <0.01 | |
| Candriam S C A | $19.09M | 0.68 | 462,554 | -5.13% | -$1.03M | 0.12 | |
| Dimensional Fund Advisors | $17.93M | 0.64 | 434,300 | -11.71% | -$2.38M | 0.01 | |
| Woodline Partners LP | $17.43M | 0.62 | 422,204 | +8.92% | +$1.43M | 0.17 | |
| RA Capital Management, L.P. | $17.39M | 0.62 | 421,348 | 0% | +$0 | 0.02 | |
| Spyglass Capital Management LLC | $16.75M | 0.59 | 405,766 | -17.05% | -$3.44M | 12.56 | |
| Voloridge Investment Management, LLC | $15.66M | 0.55 | 379,376 | +22.51% | +$2.88M | 0.04 | |
| Renaissance Technologies | $14.94M | 0.53 | 361,973 | +52.36% | +$5.14M | 0.02 | |
| Opaleye Management Inc | $13.62M | 0.48 | 330,000 | +25.14% | +$2.74M | 2.15 | |
| American Century Investments | $13.44M | 0.48 | 325,518 | -17.67% | -$2.88M | 0.01 | |
| Gilder Gagnon Howe & Co. LLC | $13.41M | 0.48 | 324,844 | -2.6% | -$358,310.39 | 0.17 | |
| D. E. Shaw & Co. | $12.53M | 0.44 | 303,638 | +257.51% | +$9.03M | 0.02 | |
| Nuveen | $12.22M | 0.43 | 296,017 | -17.36% | -$2.57M | <0.01 | |
| UBS | $12.14M | 0.43 | 294,044 | +14.42% | +$1.53M | <0.01 | |
| Frazier Life Sciences Management L P | $11.78M | 0.42 | 285,331 | 0% | +$0 | 0.61 | |
| Schonfeld Group | $11.6M | 0.41 | 281,097 | +14.33% | +$1.45M | 0.08 | |
| Nordea Investment Management Ab | $11.56M | 0.4 | 276,482 | -0.81% | -$94,259.00 | 0.01 | |
| Brown Advisory | $11.32M | 0.4 | 274,175 | +3.29% | +$360,952.32 | 0.02 | |
| Franklin Templeton Investments | $11.07M | 0.39 | 268,153 | +1,662.89% | +$10.44M | <0.01 | |
| Credit Suisse | $10.82M | 0.38 | 262,224 | +84.52% | +$4.96M | 0.01 | |
| Millennium Management LLC | $10.06M | 0.36 | 243,667 | -32.09% | -$4.75M | 0.01 | |
| Wasatch Advisors | $8.56M | 0.3 | 207,426 | -6.96% | -$640,500.46 | 0.05 | |
| Td Asset Management Inc | $8.23M | 0.29 | 199,348 | +35.66% | +$2.16M | 0.01 | |
| Ubs Asset Management Americas Inc | $8.03M | 0.28 | 194,496 | -16.39% | -$1.57M | <0.01 | |
| Amundi | $6.63M | 0.28 | 193,341 | -1.22% | -$81,575.91 | <0.01 |